ASH21

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia
Global Blood Raises $300M Via Convertible Debt Offering
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
Global Blood Raises $300M Via Convertible Debt Offering
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden

ASH21 Recent News

Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
Aptose Biosciences Inc (NASDAQ: APTO) presented data from the ongoing Phase 1/2 study of HM43239 in
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Fate Therapeutics Inc (NASDAQ: FATE) 
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), 
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) 
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
ALX Oncology Holdings Inc (NASDAQ: ALXO) presented 
Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?
X4 Pharmaceuticals Inc (NASDAQ: XFOR) shares are trading lower despite releasing what it described as 
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
Viracta Therapeutics Inc (NASDAQ: VIRX) 
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively.
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with 
JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma
Janssen, a unit of Johnson & Johnson (NYSE: JNJ), posted 
What Analysts Have To Say On Incremental IGM-2323 Data At ASH Presentation
IGM Biosciences Inc (NASDAQ: IGMS) shares plunged 
IGM Biosciences' B Cell Malignancies Trial Data Fails To Lift The Stock
IGM Biosciences Inc (NASDAQ: IGMS) has 
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, 
New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment
Bluebird Bio Inc (NASDAQ: BLUE) 
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Bluebird bio Inc (NASDAQ: BLUE) 
Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced 
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
Bristol Myers Squibb & Co (NYSE: BMY) 

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved